243 related articles for article (PubMed ID: 31221112)
1. The feasibility of universal HPV vaccination program in Shenzhen of China: a health policy analysis.
Chen R; Wong E
BMC Public Health; 2019 Jun; 19(1):781. PubMed ID: 31221112
[TBL] [Abstract][Full Text] [Related]
2. Toward universal human papillomavirus vaccination for adolescent girls in Hong Kong: a policy analysis.
Chen R; Wong E; Wu L; Zhu Y
J Public Health Policy; 2020 Jun; 41(2):170-184. PubMed ID: 32054980
[TBL] [Abstract][Full Text] [Related]
3. Implementing the free HPV vaccination for adolescent girls aged below 14 in Shenzhen, Guangdong Province of China: experience, challenges, and lessons.
Wu D; Liu P; Song D; Wang H; Chen S; Tang W; Zhao X; Zhao F; Wang Y
Infect Dis Poverty; 2023 Oct; 12(1):98. PubMed ID: 37899444
[TBL] [Abstract][Full Text] [Related]
4. Greek health professionals' perceptions of the HPV vaccine, state policy recommendations and their own role with regards to communication of relevant health information.
Karamanidou C; Dimopoulos K
BMC Public Health; 2016 Jun; 16():467. PubMed ID: 27260348
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India's universal immunization program.
Prinja S; Bahuguna P; Faujdar DS; Jyani G; Srinivasan R; Ghoshal S; Suri V; Singh MP; Kumar R
Cancer; 2017 Sep; 123(17):3253-3260. PubMed ID: 28472550
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus vaccine introduction--the first five years.
Markowitz LE; Tsu V; Deeks SL; Cubie H; Wang SA; Vicari AS; Brotherton JM
Vaccine; 2012 Nov; 30 Suppl 5():F139-48. PubMed ID: 23199957
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
[TBL] [Abstract][Full Text] [Related]
8. A Multiple Streams analysis of the decisions to fund gender-neutral HPV vaccination in Canada.
Shapiro GK; Guichon J; Prue G; Perez S; Rosberger Z
Prev Med; 2017 Jul; 100():123-131. PubMed ID: 28435081
[TBL] [Abstract][Full Text] [Related]
9. Ethical issues related to human papillomavirus vaccination programs: an example from Bangladesh.
Salwa M; Abdullah Al-Munim T
BMC Med Ethics; 2018 Jun; 19(Suppl 1):39. PubMed ID: 29945621
[TBL] [Abstract][Full Text] [Related]
10. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges.
Msyamboza KP; Mwagomba BM; Valle M; Chiumia H; Phiri T
BMC Public Health; 2017 Jun; 17(1):599. PubMed ID: 28651574
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of human papilloma virus (HPV) vaccination strategies and vaccination coverage in adolescent girls worldwide.
Owsianka B; Gańczak M
Przegl Epidemiol; 2015; 69(1):53-8, 151-5. PubMed ID: 25862448
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and acceptability of delivering adolescent health interventions alongside HPV vaccination in Tanzania.
Watson-Jones D; Lees S; Mwanga J; Neke N; Changalucha J; Broutet N; Maduhu I; Kapiga S; Chandra-Mouli V; Bloem P; Ross DA
Health Policy Plan; 2016 Jul; 31(6):691-9. PubMed ID: 26768827
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
Poljak M
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
[TBL] [Abstract][Full Text] [Related]
14. Differences in Human Papillomavirus Vaccination Among Adolescent Girls in Metropolitan Versus Non-metropolitan Areas: Considering the Moderating Roles of Maternal Socioeconomic Status and Health Care Access.
Monnat SM; Rhubart DC; Wallington SF
Matern Child Health J; 2016 Feb; 20(2):315-25. PubMed ID: 26511129
[TBL] [Abstract][Full Text] [Related]
15. Implementation of a national school-based Human Papillomavirus (HPV) vaccine campaign in Fiji: knowledge, vaccine acceptability and information needs of parents.
La Vincente SF; Mielnik D; Jenkins K; Bingwor F; Volavola L; Marshall H; Druavesi P; Russell FM; Lokuge K; Mulholland EK
BMC Public Health; 2015 Dec; 15():1257. PubMed ID: 26684658
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.
Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Burchett HED; LaMontagne DS; Watson-Jones D
Papillomavirus Res; 2017 Dec; 4():72-78. PubMed ID: 29179873
[TBL] [Abstract][Full Text] [Related]
17. Working to Increase Vaccination for Human Papillomavirus: A Survey of Wisconsin Stakeholders, 2015.
Mroz S; Zhang X; Williams M; Conlon A; LoConte NK
Prev Chronic Dis; 2017 Sep; 14():E85. PubMed ID: 28957034
[TBL] [Abstract][Full Text] [Related]
18. Early policy responses to the human papillomavirus vaccine in the United States, 2006-2010.
Laugesen MJ; Mistry R; Carameli KA; Ribisl KM; Needleman J; Bastani R
J Adolesc Health; 2014 Nov; 55(5):659-64. PubMed ID: 24928803
[TBL] [Abstract][Full Text] [Related]
19. The politics of HPV vaccination policy formation in the United States.
Abiola SE; Colgrove J; Mello MM
J Health Polit Policy Law; 2013 Aug; 38(4):645-81. PubMed ID: 23645875
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study.
Haeussler K; Marcellusi A; Mennini FS; Favato G; Picardo M; Garganese G; Bononi M; Costa S; Scambia G; Zweifel P; Capone A; Baio G
Value Health; 2015 Dec; 18(8):956-68. PubMed ID: 26686779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
